HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo aims to keep aggressive lymphoma at bay
Disease control OngoingThis study tests whether adding the drug venetoclax to standard chemotherapy can help prevent aggressive B-cell lymphomas from coming back. About 363 adults with double-hit or double-expressor lymphoma will receive either the usual chemo or the usual chemo plus venetoclax. The go…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New combo aims to extend life for elderly lymphoma patients
Disease control OngoingThis study looks at whether adding an oral drug (CC-486) to standard chemotherapy (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas live longer without their cancer returning. About 422 participants will receive either the standard tr…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC